In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

IntelGenx Technologies Corp.

http://www.intelgenx.com

Latest From IntelGenx Technologies Corp.

US FDA Picks Up The Pace Of Complete Response Letters Over June And July

The year began with an unusually low number of CRLs, but a recent burst of non-approval actions suggests a COVID-19 effect.

Complete Response Letters US FDA Performance Tracker

Keeping Track: Industry Channels Inner Gottlieb As Commissioner Departs US FDA

The latest drug development news and highlights from our US FDA Performance Tracker.

Drug Review Regulation

Hazards Ahead For New Drugs At US FDA Amid Safety Concerns, Shutdown Disruption

The pipeline for new drug candidates remains healthy as 2019 begins, with almost 40 novel agents already under FDA review. But the chances of another record-breaking year are threatened by a confluence of safety issues that are putting risk management back in the spotlight – and by the widening ripple effects of the recent US government shutdown.

Drug Review Approvals

Keeping Track: US FDA Enters Year's Final Stretch With Tsunami Of Novel Approvals

The latest drug development news and highlights from our US FDA Performance Tracker.

Drug Review Regulation
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
UsernamePublicRestriction

Register